Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Mar 7, 2017

Sanofi Pasteur and MedImmune Collaborate on Investigational Monoclonal Antibody for Illnesses Associated with RSV

Respiratory Syncytial Virus is the most common cause of lung inflammation and pneumonia in infants
Mar 7, 2017

Sanofi and Regeneron to Present New Phase 3 Praluent® (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions
Mar 4, 2017

Sanofi and Regeneron Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of Dupixent® (dupilumab) in Moderate-to-Severe Atopic Dermatitis

- Late-breaking oral abstract to be presented today at the Annual Meeting of the American Academy of Dermatology -
Feb 27, 2017

Sanofi and Regeneron to Present New Data on Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses
Feb 8, 2017

Appeals Court Grants Stay of Permanent Injunction for Praluent® (alirocumab) During Appeals Process

- Praluent continues to be available to patients in the U.S. -

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.